- A Great Ormond Street Hospital (Gosh) study has found a gentler treatment for children with relapsed leukaemia, potentially boosting survival and quality of life.
- The UKALL Rel2020 study, involving 188 children, demonstrated that less intensive chemotherapy followed by blinatumomab (a targeted immunotherapy) is safe and effective.
- The new approach achieved a 92 per cent remission rate and an 82 per cent long-term survival rate after three years, comparable to more intensive traditional treatments.
- Crucially, no patients died during the early phase of treatment, a significant improvement over traditional methods that carried substantial risks.
- The clinical trial was delivered as routine NHS care, making its results highly representative of real-world patient outcomes for acute lymphoblastic leukaemia (ALL).
IN FULL
